X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with VENUS REMEDIES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs VENUS REMEDIES - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS VENUS REMEDIES IPCA LABS/
VENUS REMEDIES
 
P/E (TTM) x 27.5 -804.4 - View Chart
P/BV x 2.1 0.2 896.2% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 IPCA LABS   VENUS REMEDIES
EQUITY SHARE DATA
    IPCA LABS
Mar-17
VENUS REMEDIES
Mar-16
IPCA LABS/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs643218 295.0%   
Low Rs50382 612.4%   
Sales per share (Unadj.) Rs254.4365.6 69.6%  
Earnings per share (Unadj.) Rs16.11.5 1,081.4%  
Cash flow per share (Unadj.) Rs29.837.9 78.5%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs194.6382.5 50.9%  
Shares outstanding (eoy) m126.2011.44 1,103.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.30.4 548.7%   
Avg P/E ratio x35.7101.0 35.3%  
P/CF ratio (eoy) x19.24.0 486.3%  
Price / Book Value ratio x2.90.4 750.7%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m72,3001,717 4,211.9%   
No. of employees `00013.31.0 1,304.2%   
Total wages/salary Rs m6,960324 2,145.4%   
Avg. sales/employee Rs Th2,413.54,100.7 58.9%   
Avg. wages/employee Rs Th523.2318.0 164.5%   
Avg. net profit/employee Rs Th152.416.7 914.7%   
INCOME DATA
Net Sales Rs m32,1064,183 767.6%  
Other income Rs m22620 1,122.9%   
Total revenues Rs m32,3324,203 769.3%   
Gross profit Rs m4,448812 548.0%  
Depreciation Rs m1,730417 414.9%   
Interest Rs m241380 63.4%   
Profit before tax Rs m2,70335 7,701.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m67518 3,730.4%   
Profit after tax Rs m2,02817 11,929.4%  
Gross profit margin %13.919.4 71.4%  
Effective tax rate %25.051.6 48.4%   
Net profit margin %6.30.4 1,554.1%  
BALANCE SHEET DATA
Current assets Rs m17,3402,771 625.8%   
Current liabilities Rs m9,5591,931 494.9%   
Net working cap to sales %24.220.1 120.8%  
Current ratio x1.81.4 126.4%  
Inventory Days Days100125 80.2%  
Debtors Days Days5754 105.8%  
Net fixed assets Rs m20,7795,328 390.0%   
Share capital Rs m252114 220.6%   
"Free" reserves Rs m24,4994,177 586.5%   
Net worth Rs m24,5534,376 561.0%   
Long term debt Rs m3,5171,911 184.1%   
Total assets Rs m39,5958,428 469.8%  
Interest coverage x12.21.1 1,119.2%   
Debt to equity ratio x0.10.4 32.8%  
Sales to assets ratio x0.80.5 163.4%   
Return on assets %5.74.7 121.7%  
Return on equity %8.30.4 2,126.3%  
Return on capital %10.56.6 158.9%  
Exports to sales %48.60-   
Imports to sales %14.220.5 69.4%   
Exports (fob) Rs m15,617NA-   
Imports (cif) Rs m4,571858 532.5%   
Fx inflow Rs m15,6170-   
Fx outflow Rs m5,828858 679.0%   
Net fx Rs m9,790-858 -1,140.6%   
CASH FLOW
From Operations Rs m2,764469 589.6%  
From Investments Rs m-1,43229 -4,903.1%  
From Financial Activity Rs m-1,591-464 343.3%  
Net Cashflow Rs m-25935 -750.1%  

Share Holding

Indian Promoters % 45.9 32.9 139.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 0.2 6,333.3%  
FIIs % 25.3 0.6 4,362.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 66.4 26.2%  
Shareholders   36,892 20,121 183.4%  
Pledged promoter(s) holding % 2.1 36.4 5.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   DISHMAN PHARMA  ELDER PHARMA  SUVEN LIFE  PANACEA BIOTECH  WOCKHARDT LTD.  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 200 Points Higher; Lupin & Axis Bank Top Gainers(09:30 am)

Majority of Asian stock indices are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.07%, while the Hang Seng is up 1.06%.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Aug 22, 2017 11:12 AM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS